SCYNEXIS (NASDAQ:SCYX) Stock Price & Analysis

–

USD

–(–)

Open

$4.77

Prev. Close

$4.70

High

$4.77

Low

$4.43

Company Profile

SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.

CEODavid Angulo

SectorHealthcare

IndustryMedical - Pharmaceuticals

Employees18

IPO DateMay 2, 2014

ExchangeNASDAQ

Exchange NameNASDAQ

CurrencyUSD

Headquarters & Contact

Address1 Evertrust Plaza

City / State / ZIPJersey City, NJ, 07302-6548

CountryUnited States

Phone201 884 5485

Websitehttps://www.scynexis.com

SCYNEXIS, Inc.

Company Profile

Recently from Cashu